JPH05262642A - 難溶性薬物の固体分散体の製造方法 - Google Patents

難溶性薬物の固体分散体の製造方法

Info

Publication number
JPH05262642A
JPH05262642A JP5006129A JP612993A JPH05262642A JP H05262642 A JPH05262642 A JP H05262642A JP 5006129 A JP5006129 A JP 5006129A JP 612993 A JP612993 A JP 612993A JP H05262642 A JPH05262642 A JP H05262642A
Authority
JP
Japan
Prior art keywords
solid dispersion
poorly soluble
soluble drug
drug
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5006129A
Other languages
English (en)
Japanese (ja)
Inventor
Minoru Nakano
實 中野
Toshinobu Uemura
俊信 植村
Shinichi Morisane
真一 森実
Kiyoshi Okuda
清 奥田
Keiko Nakada
圭子 中田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of JPH05262642A publication Critical patent/JPH05262642A/ja
Priority to NO19940291A priority Critical patent/NO322641B1/no
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP5006129A 1992-01-24 1993-01-18 難溶性薬物の固体分散体の製造方法 Pending JPH05262642A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO19940291A NO322641B1 (no) 1993-01-18 1994-01-27 Elektrisk feltterapiapparat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1079692 1992-01-24
JP4-10796 1992-01-24

Publications (1)

Publication Number Publication Date
JPH05262642A true JPH05262642A (ja) 1993-10-12

Family

ID=11760311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5006129A Pending JPH05262642A (ja) 1992-01-24 1993-01-18 難溶性薬物の固体分散体の製造方法

Country Status (6)

Country Link
US (1) US5340591A (enExample)
EP (1) EP0552708A1 (enExample)
JP (1) JPH05262642A (enExample)
KR (1) KR930016091A (enExample)
CA (1) CA2087932A1 (enExample)
TW (1) TW259712B (enExample)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08301789A (ja) * 1995-05-02 1996-11-19 Bayer Ag 活性化合物の調節された放出性を有する製剤およびそれらの製造方法
JPWO9706781A1 (enExample) * 1995-08-11 1997-02-27
WO1998001122A1 (en) * 1996-07-08 1998-01-15 Kyowa Hakko Kogyo Co., Ltd. Solid dispersions or solid dispersion preparations of tricyclic compounds
JPH10513477A (ja) * 1995-02-14 1998-12-22 ビーエーエスエフ アクチェンゲゼルシャフト 固体の作用物質製剤
JPH11130698A (ja) * 1997-10-31 1999-05-18 Freunt Ind Co Ltd アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
JP2003146878A (ja) * 2002-11-22 2003-05-21 Sawai Pharmaceutical Co Ltd ニルバジピン含有易溶性固形製剤およびその製造法
JP2003518483A (ja) * 1999-12-23 2003-06-10 エフ エイチ フォールディング アンド カンパニー リミテッド 不良溶解性の薬物に対する改良された医薬組成物
JP2003522097A (ja) * 1998-02-16 2003-07-22 フイズ インターナショナル リミテッド 可溶化デリバリーシステムおよび製造方法
JP2004505911A (ja) * 2000-08-03 2004-02-26 ファイザー・プロダクツ・インク コレステリルエステル転移蛋白質阻害薬の医薬用組成物
JP2006347939A (ja) * 2005-06-15 2006-12-28 Tokyo Printing Ink Mfg Co Ltd 薬物高分子複合体の製造方法及び薬物高分子複合体
JP2008524291A (ja) * 2004-12-22 2008-07-10 ノバルティス アクチエンゲゼルシャフト 固体医薬組成物
WO2008133102A1 (ja) 2007-04-20 2008-11-06 Daido Chemical Corporation 新規乾式固体分散体用基剤、該基剤を含有する固体分散体及び該分散体を含有する組成物
US8343547B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US8354122B2 (en) 2006-04-20 2013-01-15 Shin-Etsu Chemical Co., Ltd. Solid dispersion preparation
JP2015536978A (ja) * 2012-11-07 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド 難溶性薬物の固体分散体およびその製造方法
JP6821863B1 (ja) * 2019-08-30 2021-01-27 三栄源エフ・エフ・アイ株式会社 非晶質の難水溶性素材を含有する固体組成物、及びその製造方法
WO2021040027A1 (ja) * 2019-08-30 2021-03-04 三栄源エフ・エフ・アイ株式会社 非晶質の難水溶性素材を含有する固体組成物、及びその製造方法

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001166A1 (en) * 1993-06-30 1995-01-12 Fujisawa Pharmaceutical Co., Ltd. Encapsulated medicine
DE4401646A1 (de) * 1994-01-21 1995-07-27 Krewel Werke Gmbh Optimal freisetzende Kava-Extrakte
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
SE9502244D0 (sv) * 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
WO2002013792A1 (fr) * 2000-08-11 2002-02-21 Eisai Co., Ltd. Dispersion solide médicamenteuse à solubilité accrue
KR20020014570A (ko) * 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
PT1404300E (pt) * 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
KR20040083493A (ko) 2002-02-01 2004-10-02 화이자 프로덕츠 인크. 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출형제약상 제형
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
KR20040011248A (ko) * 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
BR0313428A (pt) 2002-08-12 2005-06-28 Pfizer Prod Inc Composições farmacêuticas de drogas semi-ordenados e polìmeros
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
WO2004069138A2 (en) * 2003-02-03 2004-08-19 Novartis Ag Pharmaceutical formulation
WO2004110354A2 (en) * 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
WO2005046644A1 (en) * 2003-11-14 2005-05-26 Pfizer Products Inc. Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
EP1694657A1 (en) * 2003-12-09 2006-08-30 Pfizer Inc. Compositions comprising an hiv protease inhibitor
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
JP2009502969A (ja) * 2005-07-28 2009-01-29 アイエスピー インヴェストメンツ インコーポレイテッド 非晶質エファビレンツ及びその製造
CA2631233C (en) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
US10189957B2 (en) * 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
US20080220029A1 (en) * 2007-03-05 2008-09-11 Charlene Ng Fast-dissolving/disintegrating film preparation having high proportion of active
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
KR101257550B1 (ko) 2007-09-10 2013-04-24 칼시메디카, 인크 세포내 칼슘을 조절하는 화합물
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
RU2490014C2 (ru) * 2007-10-05 2013-08-20 Альцгеймер'С Инститьют Оф Америка, Инк. Способ уменьшения отложения амилоида, амилоидной нейротоксичности и микроглиоза с помощью (-)-энантиомера нилвадипина
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
JP5711655B2 (ja) * 2008-03-31 2015-05-07 シマベイ セラピューティクス， インコーポレーテッド オキシメチレンアリール化合物およびその使用
CN102256969A (zh) 2008-08-27 2011-11-23 钙医学公司 调节胞内钙的化合物
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EA201201263A1 (ru) * 2010-03-08 2013-04-30 Рациофарм Гмбх Фармацевтическая композиция, содержащая этексилат дабигатрана
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
PT2563776T (pt) 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
ES2676209T3 (es) 2010-06-23 2018-07-17 Metabolex Inc. Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8921374B2 (en) 2012-06-21 2014-12-30 Mayne Pharma International Pty Ltd Itraconazole compositions and dosage forms, and methods of using the same
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
WO2015120392A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
DK3104853T3 (da) 2014-02-10 2019-12-09 Respivant Sciences Gmbh Behandling med mastcellestabilisatorer til systemiske forstyrrelser
KR101772836B1 (ko) 2014-03-17 2017-08-29 화이자 인코포레이티드 대사 및 관련 장애의 치료에 사용하기 위한 디아실글리세롤 아실트랜스퍼라제 2 억제제
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
CN109562281B (zh) 2016-05-25 2021-12-17 同心镇痛药物公司 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
JP7028860B2 (ja) 2016-08-26 2022-03-02 カーテナ ファーマシューティカルズ，インク． Ｏｌｉｇ２活性の阻害
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 肺線維症の治療のためのクロモリン組成物
MX2019010756A (es) 2017-03-10 2020-01-20 Pfizer Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
EP3706867B1 (en) 2017-11-07 2024-09-04 The Regents Of The University Of Michigan Combination of baclofen and chlorzoxazone for treatment of cerebellar ataxia
CN111542318A (zh) 2017-11-10 2020-08-14 密歇根大学董事会 Ash1l降解剂及用其进行治疗的方法
WO2019113469A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
AU2019310118A1 (en) 2018-07-27 2021-03-11 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
US12246042B2 (en) 2018-08-29 2025-03-11 Myos Corp. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
BR112021003039A2 (pt) 2018-08-31 2021-05-18 Pfizer Inc. combinações para o tratamento de nash/nafld e doenças relacionadas
US12251405B2 (en) 2018-10-03 2025-03-18 Myos Corp. Spray dried follistatin product
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
US11084825B2 (en) 2018-12-31 2021-08-10 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
WO2020160113A1 (en) 2019-02-01 2020-08-06 Myos Rens Technology Inc. Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
CA3133093A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics, Inc. Nicorandil derivatives
AU2020260018A1 (en) 2019-04-19 2021-11-04 Pfizer Inc. Anti-proliferative agents for treating PAH
WO2020234726A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
US20220363673A1 (en) 2019-06-28 2022-11-17 Pfizer Inc. 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
LT4161927T (lt) 2020-06-09 2024-09-25 Pfizer Inc. Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas
CA3185209A1 (en) 2020-07-10 2021-01-27 Alyssa WINKLER Gas41 inhibitors and methods of use thereof
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
JP2024534268A (ja) 2021-08-31 2024-09-18 セレスピア インコーポレイテッド 共結晶
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023100061A1 (en) 2021-12-01 2023-06-08 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
EP4444708B1 (en) 2021-12-06 2025-07-30 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
AU2022426699A1 (en) 2021-12-30 2024-07-11 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
US20250353854A1 (en) 2022-06-03 2025-11-20 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
IL319486A (en) 2022-10-07 2025-05-01 Pfizer HSD17B13 Inhibitors and/or Retarders
IL319392A (en) 2022-10-18 2025-05-01 Pfizer Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
EP4604955A1 (en) 2022-10-18 2025-08-27 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
AU2023363975A1 (en) 2022-10-19 2025-05-22 Myos Corp. Myogenic compounds
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
CN120731201A (zh) 2022-12-16 2025-09-30 辉瑞公司 含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250145571A1 (en) 2023-09-26 2025-05-08 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives
US20250304572A1 (en) 2024-03-29 2025-10-02 Biomea Fusion, Inc. Heterocyclic glp-1r agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540253A (en) * 1949-02-08 1951-02-06 Merck & Co Inc Granulation process
US2778768A (en) * 1953-06-19 1957-01-22 Rohm & Haas Pesticidal ethylenebisdithiocarbamates with hydroxy ethyl cellulose compositions and methods
US2980589A (en) * 1958-09-12 1961-04-18 American Cyanamid Co Process for producing anhydrous granulation of a medicinally active waterlabile powder
NL99185C (enExample) * 1959-07-30
US3692896A (en) * 1968-06-14 1972-09-19 Isumura Juntendo Co Ltd Process for the preparation of water-soluble tablets
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS603783B2 (ja) * 1977-08-10 1985-01-30 株式会社日立製作所 共通リードフレームから小リード数のリードフレームを製造する方法
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS60190723A (ja) * 1984-03-09 1985-09-28 Yamanouchi Pharmaceut Co Ltd 難溶性薬物の溶解速度向上方法
JPH0627074B2 (ja) * 1984-07-25 1994-04-13 日東電工株式会社 医薬組成物
JPS6163614A (ja) * 1984-09-04 1986-04-01 Yamanouchi Pharmaceut Co Ltd 難溶性薬物の溶解速度向上方法
JPH02279631A (ja) * 1989-04-18 1990-11-15 Yamanouchi Pharmaceut Co Ltd 薬物のシクロデキストリン包接体及びその製造法

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10513477A (ja) * 1995-02-14 1998-12-22 ビーエーエスエフ アクチェンゲゼルシャフト 固体の作用物質製剤
JPH08301789A (ja) * 1995-05-02 1996-11-19 Bayer Ag 活性化合物の調節された放出性を有する製剤およびそれらの製造方法
JPWO9706781A1 (enExample) * 1995-08-11 1997-02-27
US6462093B1 (en) 1995-08-11 2002-10-08 Nissan Chemical Industries, Ltd. Method for converting sparingly water-soluble medical substance to amorphous state
WO1998001122A1 (en) * 1996-07-08 1998-01-15 Kyowa Hakko Kogyo Co., Ltd. Solid dispersions or solid dispersion preparations of tricyclic compounds
JPH11130698A (ja) * 1997-10-31 1999-05-18 Freunt Ind Co Ltd アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
JP2003522097A (ja) * 1998-02-16 2003-07-22 フイズ インターナショナル リミテッド 可溶化デリバリーシステムおよび製造方法
JP2003518483A (ja) * 1999-12-23 2003-06-10 エフ エイチ フォールディング アンド カンパニー リミテッド 不良溶解性の薬物に対する改良された医薬組成物
JP2007314573A (ja) * 2000-08-03 2007-12-06 Pfizer Prod Inc コレステリルエステル転移蛋白質阻害薬の医薬用組成物
JP2004505911A (ja) * 2000-08-03 2004-02-26 ファイザー・プロダクツ・インク コレステリルエステル転移蛋白質阻害薬の医薬用組成物
JP2003146878A (ja) * 2002-11-22 2003-05-21 Sawai Pharmaceutical Co Ltd ニルバジピン含有易溶性固形製剤およびその製造法
JP2008524291A (ja) * 2004-12-22 2008-07-10 ノバルティス アクチエンゲゼルシャフト 固体医薬組成物
JP2006347939A (ja) * 2005-06-15 2006-12-28 Tokyo Printing Ink Mfg Co Ltd 薬物高分子複合体の製造方法及び薬物高分子複合体
US8354122B2 (en) 2006-04-20 2013-01-15 Shin-Etsu Chemical Co., Ltd. Solid dispersion preparation
US8663698B2 (en) 2006-04-20 2014-03-04 Shin-Etsu Chemical Co., Ltd. Solid dispersion preparation
US8663697B2 (en) 2006-04-20 2014-03-04 Shin-Etsu Chemical Co., Ltd. Solid dispersion preparation
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US8343547B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
WO2008133102A1 (ja) 2007-04-20 2008-11-06 Daido Chemical Corporation 新規乾式固体分散体用基剤、該基剤を含有する固体分散体及び該分散体を含有する組成物
US9101617B2 (en) 2007-04-20 2015-08-11 Daido Chemical Corporation Base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
JP2015536978A (ja) * 2012-11-07 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド 難溶性薬物の固体分散体およびその製造方法
JP6821863B1 (ja) * 2019-08-30 2021-01-27 三栄源エフ・エフ・アイ株式会社 非晶質の難水溶性素材を含有する固体組成物、及びその製造方法
WO2021040027A1 (ja) * 2019-08-30 2021-03-04 三栄源エフ・エフ・アイ株式会社 非晶質の難水溶性素材を含有する固体組成物、及びその製造方法
JP2021120368A (ja) * 2019-08-30 2021-08-19 三栄源エフ・エフ・アイ株式会社 非晶質の難水溶性素材を含有する固体組成物、及びその製造方法
US12453701B2 (en) 2019-08-30 2025-10-28 San-Ei Gen F.F.I., Inc. Solid composition containing amorphous, poorly water-soluble material, and method for producing same

Also Published As

Publication number Publication date
TW259712B (enExample) 1995-10-11
US5340591A (en) 1994-08-23
EP0552708A1 (en) 1993-07-28
CA2087932A1 (en) 1993-07-25
KR930016091A (ko) 1993-08-26

Similar Documents

Publication Publication Date Title
JPH05262642A (ja) 難溶性薬物の固体分散体の製造方法
TWI763881B (zh) 帕博西里之固態劑型
EP0411629B1 (en) A process for micronizing slightly-soluble drug
AU731176B2 (en) Improved pharmaceutical composition comprising Fenofibrate
JP2005517690A (ja) 固体薬物分散物を含有する即時放出剤形
JPS62167727A (ja) 固形ニフエジピン製剤の製造方法及びそのようにして得られた製剤
EP0602112B1 (en) High content ibuprofen agglomerates and process to prepare them
JP2001515030A (ja) 水溶性医薬品を含む放出が制御された剤型
Shah Dissolution improvement of nebivolol hydrochloride using solid dispersion adsorbate technique
JP2008540644A (ja) 新規粒質化方法及びそれから生成される粒質物
KR20070119700A (ko) 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제
US20240150304A1 (en) Formulation of metaxalone
WO1999052931A1 (fr) Dispersion solide contenant un derive d'acide sialique
JP3037393B2 (ja) 経口投与用固形薬剤の製造方法
US20240390285A1 (en) High-dose compressible dosage forms manufactured by simultaneous melt-coating and melt-granulation of active pharmaceutical ingredients
JPH05306225A (ja) 持続性製剤
WO2007073389A1 (en) Compressed solid dosage forms with drugs of low solubility and process for making the same
CA2634094A1 (en) Pharmaceutical formulations of fenofibrate having improved bioavailability
JP2007527394A (ja) 拡散層調節固体
US20070148245A1 (en) Compressed solid dosage forms with drugs of low solubility and process for making the same
JPH09309829A (ja) ニトレンジピン含有経口投与製剤およびその製造法
JPH01168619A (ja) 新規な酢酸クロルマジノン固形製剤
Swamiappan et al. Copovidone-Based Stable Nebivolol Hydrochloride Formulation: Dissolution and Characterization Studies: Stable Nebivolol Hydrochloride Formulation
JPH0215026A (ja) 新規なプロブコール固形製剤
CN106539771A (zh) 一种奥贝胆酸片及其制备方法